AUPH

7.32

1.53% 0.11

Handel nachbörslich: 7.32

Aurinia Pharmaceuticals Inc (AUPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AUPH? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$7.21

Offen:

$7.17

24-Stunden-Volumen:

953.20K

Relative Volume:

0.81

Marktkapitalisierung:

$1.03B

Einnahmen:

$175.51M

Nettoeinkommen (Verlust:

$-78.02M

KGV:

-13.81

EPS:

-0.53

Netto-Cashflow:

$-34.18M

1W Leistung:

-2.27%

1M Leistung:

+2.81%

6M Leistung:

+43.53%

1J Leistung:

-11.06%

1-Tages-Spanne:

$7.09

$7.35

1-Wochen-Bereich:

$7.03

$7.485

52-Wochen-Spanne:

$4.71

$10.05

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Firmenname

Aurinia Pharmaceuticals Inc

Sektor

Healthcare (1181)

Branche

Biotechnology (671)

Telefon

250-744-2487

Adresse

#140, 14315 - 118 AVENUE, EDMONTON, BC

Mitarbeiter

300

Twitter

@AuriniaPharma

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

AUPH's Discussions on Twitter

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-11-04	Herabstufung	Oppenheimer	Outperform → Perform
2022-05-05	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-12-10	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2021-01-25	Bestätigt	H.C. Wainwright	Buy
2020-11-03	Bestätigt	H.C. Wainwright	Buy
2020-06-17	Eingeleitet	BTIG Research	Buy
2020-05-05	Eingeleitet	Cowen	Outperform
2020-01-10	Eingeleitet	Jefferies	Buy
2019-12-16	Bestätigt	H.C. Wainwright	Buy
2018-03-16	Bestätigt	Cantor Fitzgerald	Overweight
2018-02-08	Eingeleitet	RBC Capital Mkts	Outperform
2017-10-30	Bestätigt	H.C. Wainwright	Buy
2017-05-18	Bestätigt	H.C. Wainwright	Buy
2017-04-11	Eingeleitet	Cantor Fitzgerald	Overweight
2017-03-22	Bestätigt	FBR & Co.	Outperform
2016-12-30	Bestätigt	H.C. Wainwright	Buy
2016-08-17	Bestätigt	H.C. Wainwright	Buy
2016-06-30	Eingeleitet	H.C. Wainwright	Buy
2015-05-08	Eingeleitet	MLV & Co	Buy

Alle ansehen

Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten

Nov 02, 2024

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago - Yahoo Finance

Nov 02, 2024

Oct 31, 2024

Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 30, 2024

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - The Bakersfield Californian

Oct 30, 2024

Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow

Oct 30, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) surges 5.9%; individual investors who own 51% shares profited along with institutions - Simply Wall St

Oct 30, 2024

Oct 16, 2024

Objective long/short (AUPH) Report - Stock Traders Daily

Oct 16, 2024

Oct 14, 2024

Oppenheimer Downgrades Aurinia Pharmaceuticals Inc (AUPH) to a Perform from an Outperform - Knox Daily

Oct 14, 2024

Adversity is less terrifying than hope: Aurinia Pharmaceuticals Inc (AUPH) - SETE News

Oct 14, 2024

Oct 12, 2024

AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Oct 12, 2024

AQR Capital Management LLC Buys Shares of 202,241 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Oct 12, 2024

Aurinia Pharmaceuticals spotlights lupus nephritis drug - Investing.com India

Oct 12, 2024

Oct 11, 2024

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 - BioSpace

Oct 11, 2024

Charting the Course: Aurinia Pharmaceuticals Inc’s AUPH Stock Prospects - The InvestChronicle

Oct 11, 2024

Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024 - TipRanks

Oct 11, 2024

Aurinia Pharmaceuticals spotlights lupus nephritis drug By Investing.com - Investing.com UK

Oct 11, 2024

Oct 10, 2024